GSK Plc

GSK Plc - ADR GSK

Dividend Summary

The next GSK Plc - ADR dividend went ex 16 days ago for 34.75c and will be paid in 1 month.
The previous GSK Plc - ADR dividend was 34.19c and it went ex 3 months ago and it was paid 2 months ago.
There are typically 4 dividends per year (excluding specials).

Latest Dividends
Summary Previous dividend Next dividend
Status Paid Declared
Type Quarterly Quarterly
Per share 34.19c 34.75c
Declaration date 01 Feb 2023 (Wed) 26 Apr 2023 (Wed)
Ex-div date 23 Feb 2023 (Thu) 18 May 2023 (Thu)
Pay date 13 Apr 2023 (Thu) 13 Jul 2023 (Thu)

Enter the number of GSK Plc - ADR shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
99%
Our premium tools have predicted GSK Plc - ADR with 99% accuracy.
Dividend Yield Today
4.1%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for GSK Plc - ADR
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
Forecast Quarterly 24 Feb 2028 13 Apr 2028 USD Sign up
Forecast Quarterly 18 Nov 2027 13 Jan 2028 USD Sign up
Forecast Quarterly 12 Aug 2027 07 Oct 2027 USD Sign up
Forecast Quarterly 20 May 2027 08 Jul 2027 USD Sign up
Forecast Quarterly 18 Feb 2027 08 Apr 2027 USD Sign up
Forecast Quarterly 12 Nov 2026 14 Jan 2027 USD Sign up
Forecast Quarterly 13 Aug 2026 08 Oct 2026 USD Sign up
Forecast Quarterly 14 May 2026 09 Jul 2026 USD Sign up
Forecast Quarterly 19 Feb 2026 09 Apr 2026 USD Sign up
Forecast Quarterly 13 Nov 2025 08 Jan 2026 USD Sign up
Forecast Quarterly 14 Aug 2025 09 Oct 2025 USD Sign up
Forecast Quarterly 15 May 2025 10 Jul 2025 USD Sign up
Forecast Quarterly 20 Feb 2025 10 Apr 2025 USD Sign up
Forecast Quarterly 14 Nov 2024 09 Jan 2025 USD Sign up
Forecast Quarterly 15 Aug 2024 10 Oct 2024 USD Sign up
Forecast Quarterly 16 May 2024 11 Jul 2024 USD Sign up
Forecast Quarterly 22 Feb 2024 11 Apr 2024 USD Sign up
Forecast Quarterly 16 Nov 2023 11 Jan 2024 USD Sign up
Forecast Quarterly 17 Aug 2023 12 Oct 2023 USD Sign up
Declared Quarterly 26 Apr 2023 18 May 2023 13 Jul 2023 USD 34.71c 34.75c 馃槃
Paid Quarterly 01 Feb 2023 23 Feb 2023 13 Apr 2023 USD 33.88c 34.19c 馃槃
Paid Quarterly 02 Nov 2022 17 Nov 2022 12 Jan 2023 USD 33.48c
Paid Quarterly 27 Jul 2022 18 Aug 2022 06 Oct 2022 USD 36.95c
Paid Quarterly 02 May 2022 19 May 2022 01 Jul 2022 USD 34.14c
Paid Quarterly 09 Feb 2022 24 Feb 2022 07 Apr 2022 USD 60.35c
Paid Quarterly 28 Oct 2021 18 Nov 2021 13 Jan 2022 USD 51.68c
Paid Quarterly 30 Jul 2021 19 Aug 2021 07 Oct 2021 USD 51.75c
Paid Quarterly 04 May 2021 20 May 2021 08 Jul 2021 USD 52.62c
Paid Quarterly 18 Feb 2021 08 Apr 2021 USD 63.67c
Paid Quarterly 12 Nov 2020 14 Jan 2021 USD 51.67c
Paid Quarterly 29 Jul 2020 13 Aug 2020 08 Oct 2020 USD 49.29c
Paid Quarterly 29 Apr 2020 14 May 2020 09 Jul 2020 USD 47.39c
Paid Quarterly 05 Feb 2020 20 Feb 2020 09 Apr 2020 USD 56.7c
Paid Quarterly 14 Nov 2019 09 Jan 2020 USD 49.98c
Paid Quarterly 08 Aug 2019 10 Oct 2019 USD 46.58c
Paid Quarterly 16 May 2019 11 Jul 2019 USD 47.3c
Paid Quarterly 07 Feb 2019 21 Feb 2019 11 Apr 2019 USD 60.17c
Paid Quarterly 01 Nov 2018 15 Nov 2018 10 Jan 2019 USD 48.38c
Paid Quarterly 25 Jul 2018 09 Aug 2018 11 Oct 2018 USD 49.56c
Paid Quarterly 10 May 2018 12 Jul 2018 USD 50.33c
Paid Quarterly 07 Feb 2018 22 Feb 2018 12 Apr 2018 USD 65.17c
Paid Quarterly 09 Nov 2017 11 Jan 2018 USD 50.37c
Paid Quarterly 09 Aug 2017 12 Oct 2017 USD 50.1c
Paid Quarterly 26 Apr 2017 10 May 2017 13 Jul 2017 USD 49.04c
Paid Quarterly 08 Feb 2017 22 Feb 2017 13 Apr 2017 USD 57.12c
Paid Quarterly 02 Nov 2016 12 Jan 2017 USD 46.21c
Paid Quarterly 27 Jul 2016 10 Aug 2016 13 Oct 2016 USD 46.65c
Paid Quarterly 28 Apr 2016 11 May 2016 14 Jul 2016 USD 50.02c
Paid Special 03 Feb 2016 17 Feb 2016 14 Apr 2016 USD 57.05c
Paid Quarterly 03 Feb 2016 17 Feb 2016 14 Apr 2016 USD 65.61c
Paid Quarterly 28 Oct 2015 10 Nov 2015 14 Jan 2016 USD 54.9c
Paid Quarterly 29 Jul 2015 12 Aug 2015 01 Oct 2015 USD 57.69c
Paid Quarterly 06 May 2015 13 May 2015 09 Jul 2015 USD 58.62c
Paid Quarterly 04 Feb 2015 18 Feb 2015 09 Apr 2015 USD 69.52c
Paid Quarterly 22 Oct 2014 05 Nov 2014 08 Jan 2015 USD 61.3c
Paid Quarterly 23 Jul 2014 06 Aug 2014 02 Oct 2014 USD 64.82c
Paid Quarterly 30 Apr 2014 14 May 2014 10 Jul 2014 USD 64c
Paid Quarterly 05 Feb 2014 19 Feb 2014 10 Apr 2014 USD 74.96c
Paid Quarterly 23 Oct 2013 13 Nov 2013 09 Jan 2014 USD 61.61c
Paid Quarterly 24 Jul 2013 07 Aug 2013 03 Oct 2013 USD 55.32c
Paid Quarterly 24 Apr 2013 08 May 2013 11 Jul 2013 USD 55.02c
Paid Quarterly 06 Feb 2013 20 Feb 2013 11 Apr 2013 USD 68.95c
Paid Quarterly 31 Oct 2012 14 Nov 2012 03 Jan 2013 USD 57.9c
Paid Quarterly 08 Aug 2012 04 Oct 2012 USD 52.79c
Paid Quarterly 09 May 2012 05 Jul 2012 USD 54.91c
Year Amount Change
2006 0.0c
2007 0.0c
0%
2008 0.0c
0%
2009 0.0c
0%
2010 0.0c
0%
2011 0.0c
0%
2012 234.55c
100%
2013 246.91c
5.3%
2014 259.64c
5.2%
2015 236.82c
-8.8%
2016 200.0c
-15.5%
2017 214.68c
7.3%
2018 208.44c
-2.9%
2019 200.56c
-3.8%
2020 212.02c
5.7%
2021 216.4c
2.1%
2022 138.76c
-35.9%
2023 Sign Up Required
2024 Sign Up Required
2025 Sign Up Required
2026 Sign Up Required
2027 Sign Up Required

GSK Plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
4.1%
Optimized Yield
Sign Up Required
52 Week High
5.9% on 16 February 2023
52 Week Low
3.8% on 17 May 2023
Next Ex-Div-Date Countdown
Sign Up Required

About GSK Plc

GlaxoSmithKline is a very large UK based pharmaceutical company with an excellent track record of delivering increased dividends to shareholders. In recent years it has been changing its strategy and reducing it's dependence on the pure pharmaceuticals business.

Sector
Pharmaceuticals & Biotechnology
Country
United States
Share Price
$34.11 (yesterday's closing price)
Shares in Issue
2,047 million
Market Cap
$69.8bn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
Other listings
GSK Plc
Home Page URL
https://www.gsk.com/
Investor Relations URL
Sign Up Required
Dividend History URL
Sign Up Required
Financial Calendar URL
Sign Up Required
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
Summary 路 Group sales +6% CER on a reported basis and +1% CER pro-forma - Pharmaceuticals 拢14.2 billion, -7% (-1% pro-forma); Vaccines 拢3.7 billion, +19% (+3% pro-forma); Consumer Healthcare 拢6 billion, +44% (+6% pro-forma) 路 拢2 billion of new product sales driven by HIV (Tivicay,聽Triumeq), Respiratory (Relvar/Breo,聽Anoro,Incruse) and Meningitis vaccines (Menveo,聽Bexsero) - Growing sales contribution: Q4 sales 拢682 million, (Q3: 拢591 million) - Nucala, a new biologic treatment for severe asthma, launched at the end of 2015 - New product sales now expected to reach 拢6 billion target up to two years earlier (2018 vs 2020) 路 Integration and restructuring programme on schedule - 拢1 billion incremental annual cost savings delivered in 2015 for costs of 拢1.9 billion - On track to deliver 拢3 billion of annual cost savings by end 2017 路 2015 core EPS 75.7p, -15% CER, ahead of financial guidance - Reflects short-term dilution from transaction partly offset by integration and restructuring benefits 路 2015 total EPS 174.3p, +>100% CER - Reflects impact of transaction gains, partly offset by restructuring charges and revaluation of the contingent consideration relating to improved outlook for HIV business 路 2016 core EPS percentage growth expected to reach double digits CER - If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth 路 2015 ordinary dividend of 80p and special dividend of 20p confirmed - Special dividend to be paid alongside Q4 ordinary dividend in April 2016 - Continue to expect 80p full year dividend for 2016 and 2017 路 New R&D portfolio of ~40 assets to drive long-term performance; multiple development milestones expected in 2016/2017 - Up to 10 regulatory filings include聽Shingrix聽(shingles vaccine), sirukumab (RA),聽Benlysta聽SC (lupus) and ICS/LABA/LAMA (COPD) - Up to 10 Phase lll starts include cabotegravir (HIV), daprodustat (anaemia) and Men ABCWY vaccine - Up to 20 Phase ll starts in Immuno-inflammation, Oncology, Respiratory and Infectious diseases - Estimated R&D rate of return maintained at 13%
DividendMax Limited
Summary 路 Group sales +7% CER on a reported basis and +2% CER pro-forma - Pharmaceuticals 拢3.5 billion, -6% (+2% pro-forma); Vaccines 拢0.8 billion, +11% (-5% pro-forma); Consumer Healthcare 拢1.5 billion, +51% (+6% pro-forma) - New Pharmaceutical and Vaccine sales of 拢446 million in Q2 路 Q2 core EPS of 17.3p, flat in CER terms - EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions - Integration of new Consumer and Vaccine businesses on track - On track to deliver targeted annual cost savings of 拢3 billion from all restructuring programmes 路 Total Q2 EPS of 3.1p and H1 EPS of 170.7p - Reflects phasing of pre-tax transaction gains and accelerated restructuring charges 路 2015 earnings guidance and 2016 outlook reiterated - Expect 2015 core EPS to decline at a high teen percentage rate (CER) - 2016 core EPS percentage growth expected to reach double digits (CER) 路 Q2 dividend of 19p declared - Continued expectation for full year dividend of 80p 路 R&D innovation with significant potential to drive long-term Group performance - Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan - Positive CHMP decision received for Mosquirix - Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases - New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
DividendMax Limited
DividendMax Limited
DividendMax Limited
Summary 鈻 Broadly-based sales growth with Group turnover +1% CER: 聽 - Pharmaceuticals and Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%, impacted by decline in China sales and Vaccines phasing 聽 - Consumer Healthcare +4% 聽 - Total Group turnover ex-divestments +1% 聽 聽 鈻 Further significant pipeline approvals and filings: 聽 - 4 approvals; US: Tivicay for HIV and FluLaval Q-IV vaccine for flu; Europe: Tafinlar for metastatic melanoma; Japan: Relvar Ellipta for asthma 聽 - Positive FDA Adcom recommendation for Anoro Ellipta in COPD and positive CHMP opinion for Relvar Ellipta in asthma & COPD 聽 - 3 FDA filings: Arzerra for first-line CLL; dolutegravir-Trii for HIV; fluticasone furoate monotherapy for asthma 聽 聽 鈻 Continued delivery of operating and financial efficiencies, strong cash generation and returns to shareholders: 聽 - Net cash inflow from operating activities of 拢2.1 billion; core tax rate 23.5% 聽 - Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies 聽 - Q3 dividend: 19p (+6%) 聽 - 拢1 billion of shares repurchased by the end of Q3; continue to target 拢1-2 billion for the year 聽 聽 聽 鈻 Successful implementation of measures to drive strategic focus and improve growth outlook: 聽 - Agreement to divest Lucozade and Ribena to Suntory for 拢1.35 billion and Arixtra/Fraxiparine and related manufacturing site to Aspen for 拢700 million 聽 聽 鈻 Full year 2013 guidance reaffirmed: 聽 - Core EPS growth of 3-4% on sales growth of around 1% (both CER)
DividendMax Limited
DividendMax Limited